S-1: Scorpius Holdings Eyes $11.5 Million Capital Raise Through Public Offering of Common Stock and Pre-Funded Warrants

Scorpius Holdings is undertaking a public offering to raise $11.5 million through the sale of common stock and pre-funded warrants, aiming to bolster working capital and for general corporate purposes.

Summary

• Scorpius Holdings, a contract development and manufacturing organization (CDMO), has filed a registration statement for a proposed public offering.
• The offering includes 58,823,529 shares of common stock and pre-funded warrants to purchase up to 58,823,529 additional shares.
• The assumed public offering price is $0.17 per share, based on the last reported sale price on the NYSE American on April 26, 2024.
• The company intends to use the net proceeds, estimated at $8.8 million (or $10.2 million if the underwriters exercise their over-allotment option), for working capital, general corporate purposes, and repayment of a $750,000 note.
• ThinkEquity LLC is acting as the representative of the underwriters for the offering.
• The offering also includes an over-allotment option for the underwriters to purchase up to 8,823,529 additional shares and/or pre-funded warrants.
• The pre-funded warrants will have an exercise price of $0.0002 per share and are immediately exercisable.
• Elusys Holdings has agreed to purchase a 1% non-convertible promissory note due July 1, 2024 in the principal amount of $750,000 (the New Note) for $750,000 in cash and agreed to issue to Elusys Holdings an amended and restated 1% convertible promissory note in the principal amount of $2,250,000 with a maturity date of September 1, 2025 (the Restated Note) in exchange for the Original Convertible Note.
• If this offering is completed and based on the assumed public offering price in this offering, upon conversion of the Restated Note (exclusive of interest), Elusys Holdings would be issued 12,224,571 shares of the Company's common stock.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the capital raise is a positive step for the company's financial stability, the low offering price, auditor's concerns about going concern, and potential dilution of existing shareholders temper the overall sentiment.

Positives

• The offering will provide Scorpius Holdings with additional capital to fund its operations and strategic initiatives.
• Repayment of the New Note will reduce the company's short-term debt obligations.
• The over-allotment option provides flexibility for the underwriters to manage demand and potentially increase the offering size.
• The pre-funded warrants offer an alternative investment option for purchasers who may be limited in their ability to own common stock directly.
• The company has a relationship with ThinkEquity LLC, who has acted as underwriter in previous offerings.

Negatives

• The offering will dilute existing shareholders' ownership.
• The assumed offering price of $0.17 per share is significantly lower than historical prices, potentially indicating a distressed valuation.
• The company has a history of losses and may require additional financing in the future.
• There is no established public trading market for the pre-funded warrants, which may limit their liquidity.
• The company's ability to continue as a going concern is subject to substantial doubt, as noted by its auditors.

Risks

• Investing in Scorpius Holdings' common stock involves a high degree of risk, as detailed in the 'Risk Factors' section of the prospectus.
• The company's financial statements have been prepared assuming it will continue as a going concern, but there is substantial doubt about its ability to do so.
• The company may not be able to raise additional capital on acceptable terms, or at all.
• The company's management has broad discretion in using the net proceeds from the offering.
• The company does not anticipate paying any cash dividends on its common stock in the foreseeable future.
• The company's failure to meet the continued listing requirements of the NYSE American could result in a de-listing of its common stock.
• The company is subject to Section 203 of the DGCL, which could prevent a takeover attempt that a stockholder might consider to be in its best interests.

Future Outlook

The company believes the net proceeds of this offering will fund its operations through June 2025 after the closing of this offering.

Industry Context

The company operates as a CDMO, providing biologics manufacturing services to the biotechnology and biopharmaceutical industries. This offering reflects the capital-intensive nature of the CDMO business and the need for ongoing investment in facilities and capabilities.

Comparison to Industry Standards

• It is difficult to compare Scorpius Holdings directly to industry standards without more specific financial data and operational metrics.
• However, comparable companies in the CDMO space include Lonza, Catalent, and Thermo Fisher Scientific.
• These companies typically have higher revenue and market capitalization than Scorpius Holdings.
• The success of Scorpius Holdings will depend on its ability to secure contracts, maintain quality standards, and efficiently manage its operations.

Related Party Transactions

• Elusys Holdings purchased a convertible promissory note in the aggregate amount of $2,250,000.
• Elusys Holdings agreed to purchase a 1% non-convertible promissory note due July 1, 2024 in the principal amount of $750,000.
• Elusys Holdings agreed to issue an amended and restated 1% convertible promissory note in the principal amount of $2,250,000 with a maturity date of September 1, 2025 in exchange for the Original Convertible Note.

Stakeholder Impact

• Shareholders will experience dilution of their ownership.
• Employees may benefit from the company's improved financial stability.
• Customers may benefit from the company's ability to invest in its operations and services.
• Creditors may benefit from the company's improved financial position and ability to repay its debts.

Next Steps

• The company will proceed with the public offering, subject to market conditions and regulatory approvals.
• The company will use the net proceeds to fund its operations and strategic initiatives.
• The company will need to demonstrate improved financial performance to alleviate concerns about its long-term viability.

Key Dates

Keywords

public offering, common stock, pre-funded warrants, Scorpius Holdings, ThinkEquity, capital raise, biologics, CDMO, dilution, NYSE American